Are patients with diabetes more susceptible to open angle glaucoma?

Article

Dr Vikas Shankar has found that in the diabetic population with OAG, the optic nerve damage occurs at a lower intraocular pressure in comparison with the non-diabetic OAG population and asks: does screening hold the key?

Key Points

Our clinical examination included measurement of refraction and intraocular pressure (IOP), gonioscopy and disc assessment. Those who were suspected or diagnosed glaucomatous were admitted as inpatients for further 24-hour phasing of IOPs. Automated visual field1 24-2 along with optic disc assessment with photograph by a fundus camera were also carried out. Following these examinations, patients with a definitive diagnosis of OAG were included in the study. Patients were excluded if the media remained hazy, with non-visualization of the disc or if the patient was not co-operative with the visual field parameters.

What we found

The male:female ratio of the total sample size was 5937:5550 (male, 51.7%; female, 48.3%). Of the primary open angle glaucoma (POAG) patients with refractive error, 30.4% were seen to have myopia in the right eye and 32.1% in the left eye; 35% recorded hypermetropia in the right eye and 33% in the left eye. The degree of hypermetropia was usually in the lower range. Myopia appears to have a correlation to OAG, which was present in 4.2% of eyes with low myopia and 4.4% of eyes with moderate-to-high myopia, compared with 1.5% of eyes without myopia.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.